Masson, David <br/><br/>
Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.  [electronic resource] 

 -  Arteriosclerosis, thrombosis, and vascular biology  Dec 2009 
 - 2054-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4636 
<br/><br/><label>Standard No.: </label>10.1161/ATVBAHA.109.191320  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Animals<br/>Apolipoprotein A-I--blood<br/>Atherosclerosis--blood<br/>Cholesterol Ester Transfer Proteins--blood<br/>Cholesterol Esters--blood<br/>Cholesterol, HDL--blood<br/>Diet, Atherogenic<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Lipoproteins, HDL--blood<br/>Liver--metabolism<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Inbred DBA<br/>Mice, Knockout<br/>Mice, Transgenic<br/>Middle Aged<br/>Phenylenediamines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Receptors, LDL--deficiency<br/>Scavenger Receptors, Class B--antagonists & inhibitors<br/>Sulfonamides--pharmacology<br/>p38 Mitogen-Activated Protein Kinases--antagonists & inhibitors